



Johnson & Johnson COVID-19 Vaccinations Resume Following CDC and FDA Decision

[Learn More](#)



LATEST NEWS

8 Things to Know About Johnson & Johnson's Janssen COVID-19 Vaccine

As the company announces that its single-dose Janssen COVID-19 Vaccine has been granted Emergency Use Authorization by the U.S. Food and Drug Administration, here are some key facts about how it works (hint: it involves an inactivated common cold virus), how it has been studied, how it would be transported—and more.

By **Johnson & Johnson**, February 27, 2021



This site uses cookies as described in our [Cookie Policy](#). Please click the "Accept" button or continue to use our site if you agree to our use of cookies.


Accept

8 Things to Know About Johnson & Johnson's Janssen COVID-19 Vaccine

2 Things to Know About How It Works

Our Janssen COVID-19 Vaccine is an adenovirus vaccine

This means it uses an adenovirus—a type of virus that causes the common cold, which has been inactivated—to carry a gene from the coronavirus into human cells. The cells then produce coronavirus proteins (not the virus itself) to mimic the virus, which helps prime the immune system to fight off later infection if the body encounters the coronavirus.



It is administered in 1 vaccination

Our Janssen COVID-19 Vaccine was tested to prime the immune system using a single dose.



This site uses cookies as described in our [Cookie Policy](#). Please click the "Accept" button or continue to use our site if you agree to our use of cookies.

Accept



Endpoint \ 'en(d)-,póint \ :
This is the primary result measured by researchers

Our endpoint looked at whether our vaccine prevents someone from getting sick with moderate to severe COVID-19—meaning they show at least two symptoms, such as a fever and a cough—and if that person has a positive PCR test, which detects the virus' genetic material. We measured this at different timepoints to see when the protection might kick in.

About 1 month: The length of time that study investigators observed between when participants received the vaccine and showed peak immunity

Study investigators evaluated participants at 28 days post vaccination (as well as after 14 days) to assess whether protection had been achieved. With vaccinations, it typically takes a few weeks for the immune system to produce enough antibodies against a disease to convey immunity.



3 Things to Know About Manufacturing and Distribution



9 worldwide manufacturing sites are activating to produce the Janssen COVID-19 Vaccine

Due to the immense scale of the pandemic, we have expanded our manufacturing capacity. In addition to our existing facilities in Leiden, the Netherlands, we have entered into agreements to collaborate with eight external manufacturers around the globe, including in France, Italy, Spain and the U.S.

36-46° F is the temperature at which our Janssen COVID-19 Vaccine may remain stable for a maximum of 3 months

This is about the temperature of your home




This site uses cookies as described in our [Cookie Policy](#). Please click the "Accept" button or continue to use our site if you agree to our use of cookies.

Accept



Did you like reading this story? Click the heart to show your love.

♥ 1K



How Johnson & Johnson is Tackling the COVID-19 Pandemic

Learn about the innovative ways the company is working to combat the global outbreak caused by the novel coronavirus.

[Read more](#)

Innovation

Johnson & Johnson

Janssen

COVID-19

Vaccines


Supply chain

Ebola



This site uses cookies as described in our [Cookie Policy](#). Please click the "Accept" button or continue to use our site if you agree to our use of cookies.

Accept




LATEST NEWS April 27, 2021

Johnson & Johnson Named to the TIME100 Most Influential Companies List



LATEST NEWS April 20, 2021

What You Need to Know About Johnson & Johnson's 2021 First-Quarter Earnings



This site uses cookies as described in our [Cookie Policy](#). Please click the "Accept" button or continue to use our site if you agree to our use of cookies.

Accept

LATEST NEWS March 10, 2021

Johnson & Johnson Chairman and CEO Appears at the White House to Discuss the Company's Collaboration with Merck and Future Vaccine Production

All contents © Copyright Johnson & Johnson Services, Inc.1997-2021. All Rights Reserved.



This site uses cookies as described in our [Cookie Policy](#). Please click the "Accept" button or continue to use our site if you agree to our use of cookies.

Accept